Biocon Biologics Ltd. (BBL), through its Malaysian arm Biocon Sdn. Bhd., has delivered over 100 million cartridges of recombinant human insulin (rh-insulin) to Malaysia’s Ministry of Health (MoH). The company has been supplying insulin to Malaysia since 2016, supporting diabetes management efforts across the country.
As part of a long-standing public-private partnership with the Malaysian government, Biocon Biologics has helped serve around 345,000 patients by making rh-insulin more accessible. The collaboration is aimed at supporting local healthcare needs through stable supply and improved access to affordable insulin therapy.
The company’s insulin manufacturing facility in Johor, established with a cumulative investment of $600 million since 2011, functions as a Center of Excellence (CoE) for insulin production. The facility is equipped to manufacture various types of insulin—regular, basal, and rapid-acting—in formats such as cartridges and delivery devices. The site has been acknowledged by the Malaysia Book of Records as the country’s first and largest integrated insulin manufacturer.
Globally, Biocon Biologics has distributed over 9.2 billion doses of rh-Insulin and Insulin Glargine to patients, as part of its wider effort to support insulin access worldwide.
